{
    "nct_id": "NCT06679582",
    "official_title": "A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)",
    "inclusion_criteria": "* AML with CBFA2T3::GLIS2 gene fusion centrally confirmed\n* Refractory or relapsed disease with ≥ 5% bone marrow involvement with leukemic blasts by morphology\n* Age < 12 years.\n* Lansky performance of ≥ 50\n* Adequate organ functions\nHealthy volunteers allowed\nMust have minimum age of 1 Day\nMust have maximum age of 12 Years",
    "exclusion_criteria": "* Active central nervous system (CNS) disease (CNS3)\n* Pre-existing clinically significant corneal disorders or constitutional diseases associated with an increased risk of AML treatment toxicities\n* Active or uncontrolled infections or other active severe intercurrent illnesses,\n* Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor\n* History of allogeneic hematopoietic stem cell transplant or any organ transplant in the prior 84 days\n* Graft versus host disease (GVHD) of any grade or GVHD treatment with exception of low dose steroids",
    "miscellaneous_criteria": ""
}